KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 2243 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. PMID 36426410 · Cancer · 2023-Feb-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer. PMID 36844136 · World J Gastroenterol · 2023-Feb-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. PMID 36765311 · BMC Cancer · 2023-Feb-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. PMID 36130300 · Blood · 2023-Feb-09 While the record describes a Phase III randomized trial with a drug intervention (ixazomib) and a time-to-event endpoint (PFS), it is a secondary/post-hoc analysis of MRD dynamics and prognostication, not the original primary efficacy result report of the trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. PMID 36798177 · Res Sq · 2023-Feb-08 The study is a prognostic/biomarker analysis from a Phase 3 trial and does not report a primary/key secondary time-to-event efficacy endpoint as required for eligibility.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. PMID 36739285 · NPJ Breast Cancer · 2023-Feb-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Advances in antibody-drug conjugates for gynecologic malignancies. PMID 36484278 · Curr Opin Obstet Gynecol · 2023-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial. PMID 36150450 · Int J Radiat Oncol Biol Phys · 2023-Feb-01 The record describes a Phase II non-randomized radiation therapy trial with a toxicity primary endpoint and a secondary efficacy endpoint (freedom from biochemical/clinical failure) that is not a standard time-to-event endpoint (like OS, PFS, DFS, etc.) nor reported with Kaplan-Meier or HR. It fails on multiple key eligibility criteria: it is not Phase III, not randomized, and lacks a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial. PMID 35907513 · Int J Radiat Oncol Biol Phys · 2023-Feb-01 The study is a Phase II randomized trial in prostate cancer with a drug intervention (metformin), but its primary endpoints are anthropometric and metabolic parameters (weight, waist circumference, LDL cholesterol), not time-to-event efficacy outcomes (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). It does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. PMID 36876172 · Breast Care (Basel) · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 5 Figure · 5 Panel · risk not_visible
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. PMID 36872922 · Liver Cancer · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. PMID 36872921 · Liver Cancer · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter? PMID 36848611 · JCO Precis Oncol · 2023-Feb The record describes a secondary analysis of a Phase III randomized trial (IMvigor211) evaluating atezolizumab versus chemotherapy in urothelial carcinoma. While it is a human oncology randomized trial with a drug intervention and reports original results, it does not meet the core eligibility criterion of having a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as the focus of the report. The study's primary aim is to assess variability in lesion kinetics and its impact on survival modeling, not to report the trial's formal efficacy outcomes. Therefore, it is excluded as a secondary analysis without a primary time-to-event efficacy result.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Donafenib in hepatocellular carcinoma. PMID 36811408 · Drugs Today (Barc) · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis. PMID 36713467 · EClinicalMedicine · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data. PMID 36634532 · ESMO Open · 2023-Feb The record is a narrative review article summarizing 12 trial presentations, not an original result report of a single randomized trial. It therefore fails the 'original_result' criterion. Furthermore, it does not focus on a specific drug intervention for a single trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. PMID 36564284 · Ann Oncol · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis. PMID 36549170 · Breast · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. PMID 36549127 · ESMO Open · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives. PMID 36537831 · Urologia · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A connection between survival multistate models and causal inference for external treatment interruptions. PMID 36464917 · Stat Methods Med Res · 2023-Feb The record is a methodological paper discussing statistical approaches (multistate models, causal inference) to handle treatment interruptions in the context of a Phase III trial (START). It does not report the original efficacy results of a drug intervention trial; instead, it uses the trial as an example to illustrate a statistical method. Therefore, it fails the 'original_result' and 'drug_intervention' criteria.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review. PMID 36372736 · Eur Urol Oncol · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. PMID 36282773 · Leuk Lymphoma · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study. PMID 36156455 · Cancer Med · 2023-Feb The record describes a retrospective, real-world, multicenter study, not a randomized controlled trial. Therefore, it does not meet the core requirement of being a randomized trial (Phase III/IIIb or Phase II/III) with a drug intervention for the primary analysis. It is excluded based on being non-randomized and not a prospective randomized trial report.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. PMID 36115928 · Ann Surg Oncol · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. PMID 36030506 · Cancer Med · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers: a meta-analysis of randomized controlled trials. PMID 36017642 · Immunopharmacol Immunotoxicol · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data. PMID 35920297 · Cancer Med · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Hepatitis D: A Review. PMID 37943548 · JAMA · 2023-Dec-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Alliance for Clinical Trials in Oncology (Alliance) trial A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). PMID 38196590 · Res Sq · 2023-Dec-23 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study. PMID 37555463 · Oncologist · 2023-Dec-11 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Frontline treatment options for higher-risk MDS: can we move past azacitidine? PMID 38066872 · Hematology Am Soc Hematol Educ Program · 2023-Dec-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Development of a nomogram to predict survival in advanced biliary tract cancer. PMID 38057434 · Sci Rep · 2023-Dec-06 The record describes a nomogram development study using data from two clinical trials (JCOG1113 phase III, JCOG0805 phase II). It is not a primary report of a randomized trial with a time-to-event efficacy endpoint. The study is a secondary, predictive modeling analysis, not an original trial result report. While the underlying trials were randomized and drug-intervention studies, the article itself does not present the primary efficacy results (e.g., OS, PFS with Kaplan-Meier curves or HR) of either trial; it uses patient-level data to build and validate a prognostic nomogram. Therefore, it fails the 'original_result' and 'time_to_event' criteria for inclusion in the cohort.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis. PMID 37540222 · J Natl Cancer Inst · 2023-Dec-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial. PMID 38042834 · Trials · 2023-Dec-02 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
ReIGNITE Radiation Therapy Boost: A Prospective, International Study of Radiation Oncologists' Accuracy in Contouring Prostate Tumors for Focal Radiation Therapy Boost on Conventional Magnetic Resonance Imaging Alone or With Assistance of Restriction Spectrum Imaging. PMID 37453559 · Int J Radiat Oncol Biol Phys · 2023-Dec-01 The record describes a study about radiation contouring accuracy for a radiation therapy boost, referencing a Phase III trial. However, this specific paper is not a report of a randomized drug trial with a primary time-to-event efficacy endpoint. It is a methodological/accuracy study within oncology.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Follow-up of a Randomized Controlled Trial on Accelerated Radiation Therapy Versus Standard Fractionated Radiation Therapy for Early Glottic Cancer (JCOG0701A3). PMID 37414261 · Int J Radiat Oncol Biol Phys · 2023-Dec-01 Eligible criteria met for oncology, human, randomized, phase III, and time-to-event endpoints, but excluded because the intervention is not drug-containing (it compares radiation fractionation schedules).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG/TROG/NHMRC CTC/EORTC/CCTG). PMID 37393022 · Int J Radiat Oncol Biol Phys · 2023-Dec-01 The abstract describes a quality assurance sub-study of a Phase III randomized trial, focusing on radiation therapy planning compliance and outcomes. It does not report any primary or secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS) with Kaplan-Meier estimates or hazard ratios. Therefore, it is not eligible for inclusion in the oncology Kaplan-Meier digitization cohort.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Natural orifice specimen extraction surgery versus small-incision assisted laparoscopic radical right hemicolectomy. PMID 38108112 · Future Oncol · 2023-Dec 干预为非药物单独策略,未满足药物干预要求。
H S B
严格 v3 独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial. PMID 38024477 · EClinicalMedicine · 2023-Dec The report is a Phase 2 randomized trial in oncology with a drug intervention and time-to-event efficacy endpoints (e.g., overall survival). However, it is not a Phase III/IIIb trial as required for eligibility.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). PMID 37992595 · Lung Cancer · 2023-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma. PMID 37954037 · Eur Urol Open Sci · 2023-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 6 Figure · 10 Panel · risk visible
Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions. PMID 37934397 · Drug Saf · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. PMID 37925894 · Oral Oncol · 2023-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus? PMID 37921936 · World J Urol · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis. PMID 37865896 · J Thorac Oncol · 2023-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis. PMID 37741447 · Value Health · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756). PMID 37698632 · World J Urol · 2023-Dec 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. PMID 37666383 · Am J Obstet Gynecol · 2023-Dec The study is a Phase 3, randomized, placebo-controlled trial of a drug-containing intervention (relugolix combination therapy) for uterine fibroids, which are benign neoplasms, not malignant. Therefore, it is excluded based on the oncology criterion. Additionally, the primary efficacy endpoint is a binary proportion at week 76, not a time-to-event endpoint such as OS, PFS, DFS, etc., with Kaplan-Meier or hazard ratio analysis. While 'time to menstrual blood loss volume ≥80 mL' is listed as a secondary endpoint, the report does not present it as a primary or key secondary efficacy endpoint with formal survival analysis (e.g., KM curves, HR).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis. PMID 37461140 · BJU Int · 2023-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -